Stonier P D
J Clin Psychiatry. 1984 Apr;45(4 Pt 2):89-95.
The tolerability and safety of nomifensine in clinical practice are reviewed in the context of relevant topics for the second-generation antidepressants. Nomifensine is nonsedating and impairs neither psychomotor nor cognitive performance. It has minimal anticholinergic-like properties and is nontoxic to the heart and cardiovascular system at therapeutic dosage. It is nonepileptogenic. There are few relevant drug interactions, and overdose data to date show no serious sequelae resulting from the drug itself. Side effects include sleep disturbance, restlessness, and nausea; rare adverse reactions are in keeping with other antidepressants. Nomifensine's profile differentiates it from other commonly used antidepressants; the implications of this for treatment of both common depressions and specific at-risk patients are discussed.
在第二代抗抑郁药的相关主题背景下，对诺米芬辛在临床实践中的耐受性和安全性进行了综述。诺米芬辛无镇静作用，既不损害精神运动功能也不损害认知能力。它具有极小的类抗胆碱能特性，在治疗剂量下对心脏和心血管系统无毒。它不会诱发癫痫。相关的药物相互作用很少，迄今为止的过量用药数据表明该药物本身不会导致严重的后遗症。副作用包括睡眠障碍、烦躁不安和恶心；罕见的不良反应与其他抗抑郁药一致。诺米芬辛的特性使其有别于其他常用的抗抑郁药；文中讨论了这一点对常见抑郁症和特定高危患者治疗的影响。
